|
EA018573B1
(ru)
|
2006-09-22 |
2013-09-30 |
Фармасайкликс, Инк. |
Ингибиторы тирозинкиназы брутона
|
|
US8809273B2
(en)
|
2007-03-28 |
2014-08-19 |
Pharmacyclics, Inc. |
Inhibitors of Bruton's tyrosine kinase
|
|
US20090301928A1
(en)
*
|
2008-06-05 |
2009-12-10 |
United Comb & Novelty Corporation |
Packaging For Lipped Containers
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
SG10201510696RA
(en)
|
2008-06-27 |
2016-01-28 |
Celgene Avilomics Res Inc |
Heteroaryl compounds and uses thereof
|
|
CN105362277A
(zh)
*
|
2008-07-16 |
2016-03-02 |
药品循环有限公司 |
用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
|
|
JP5918693B2
(ja)
|
2009-05-05 |
2016-05-18 |
ダナ ファーバー キャンサー インスティテュート インコーポレイテッド |
Ｅｇｆｒ阻害剤及び疾患の治療方法
|
|
US7741330B1
(en)
*
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
|
CA3007787C
(en)
|
2010-06-03 |
2020-03-10 |
Pharmacyclics Llc |
The use of inhibitors of bruton's tyrosine kinase (btk)
|
|
AU2011276955B2
(en)
|
2010-07-09 |
2014-11-06 |
The Walter And Eliza Hall Institute Of Medical Research |
Protein kinase inhibitors and methods of treatment
|
|
MY160734A
(en)
*
|
2010-08-10 |
2017-03-15 |
Celgene Avilomics Res Inc |
Besylate salt of a btk inhibitor
|
|
NZ710636A
(en)
|
2010-11-01 |
2017-02-24 |
Celgene Avilomics Res Inc |
Heterocyclic compounds and uses thereof
|
|
WO2012061303A1
(en)
|
2010-11-01 |
2012-05-10 |
Avila Therapeutics, Inc. |
Heteroaryl compounds and uses thereof
|
|
WO2012064706A1
(en)
|
2010-11-10 |
2012-05-18 |
Avila Therapeutics, Inc. |
Mutant-selective egfr inhibitors and uses thereof
|
|
ES2759615T3
(es)
|
2011-04-01 |
2020-05-11 |
Univ Utah Res Found |
Análogos de N-fenilpirimidina-2-amina sustituidos como inhibidores de la quinasa AXL
|
|
WO2012135801A1
(en)
*
|
2011-04-01 |
2012-10-04 |
University Of Utah Research Foundation |
Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
|
|
PL2710007T3
(pl)
*
|
2011-05-17 |
2020-06-01 |
The Regents Of The University Of California |
Inhibitory kinazy
|
|
US9376438B2
(en)
|
2011-05-17 |
2016-06-28 |
Principia Biopharma, Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
|
US8962831B2
(en)
*
|
2011-05-17 |
2015-02-24 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
MX2014000130A
(es)
*
|
2011-06-28 |
2014-05-01 |
Pharmacyclics Inc |
Procedimientos y composiciones para la inhibicion de resorcion osea.
|
|
BR112014000653A2
(pt)
*
|
2011-07-13 |
2017-02-14 |
Pharmacyclics Inc |
inibidores de tirosina quinase de bruton
|
|
PL3409278T3
(pl)
|
2011-07-21 |
2021-02-22 |
Sumitomo Pharma Oncology, Inc. |
Heterocykliczne inhibitory kinazy białkowej
|
|
CA2853498A1
(en)
|
2011-10-28 |
2013-05-02 |
Celgene Avilomics Research, Inc. |
Methods of treating a bruton's tyrosine kinase disease or disorder
|
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
|
WO2013118817A1
(ja)
*
|
2012-02-07 |
2013-08-15 |
大鵬薬品工業株式会社 |
キノリルピロロピリミジン化合物又はその塩
|
|
RU2581039C1
(ru)
*
|
2012-02-23 |
2016-04-10 |
Тайхо Фармасьютикал Ко., Лтд. |
Хинолилпирролпиримидильное конденсированное соединение или его соль
|
|
BR112014022789B1
(pt)
|
2012-03-15 |
2022-04-19 |
Celgene Car Llc |
Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo
|
|
SMT201800571T1
(it)
|
2012-03-15 |
2019-01-11 |
Celgene Car Llc |
Sali di un inibitore di chinasi del recettore del fattore di crescita dell’epidermide
|
|
US9522917B2
(en)
|
2012-04-11 |
2016-12-20 |
Acerta Pharma B.V. |
Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
|
|
JP6182593B2
(ja)
|
2012-04-20 |
2017-08-16 |
アドヴィーナス セラピューティクス リミテッド |
置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
|
|
WO2013157021A1
(en)
|
2012-04-20 |
2013-10-24 |
Advinus Therapeutics Limited |
Bicyclic compounds, compositions and medicinal applications thereof
|
|
RU2678767C2
(ru)
*
|
2012-05-31 |
2019-02-01 |
ГБ005, Инк. |
Ингибиторы протеинкиназ
|
|
EA201492082A1
(ru)
|
2012-06-04 |
2015-03-31 |
Фармасайкликс, Инк. |
Кристаллические формы ингибитора тирозинкиназы брутона
|
|
CA2879570A1
(en)
|
2012-07-24 |
2014-01-30 |
Pharmacyclics, Inc. |
Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
|
|
AU2013312296B2
(en)
|
2012-09-10 |
2017-06-22 |
Principia Biopharma Inc. |
Pyrazolopyrimidine compounds as kinase inhibitors
|
|
EP2903972B1
(en)
|
2012-10-04 |
2019-12-04 |
University of Utah Research Foundation |
Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
|
|
CA2887465A1
(en)
|
2012-10-04 |
2014-04-10 |
University Of Utah Research Foundation |
Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
|
|
MX2015006168A
(es)
|
2012-11-15 |
2015-08-10 |
Pharmacyclics Inc |
Compuestos de pirrolopirimidina como inhibidores de quinasas.
|
|
CN103848810A
(zh)
|
2012-11-30 |
2014-06-11 |
北京赛林泰医药技术有限公司 |
鲁顿酪氨酸激酶抑制剂
|
|
US9126950B2
(en)
|
2012-12-21 |
2015-09-08 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
US9561228B2
(en)
|
2013-02-08 |
2017-02-07 |
Celgene Avilomics Research, Inc. |
ERK inhibitors and uses thereof
|
|
WO2014129596A1
(ja)
*
|
2013-02-22 |
2014-08-28 |
大鵬薬品工業株式会社 |
三環性化合物の製造方法及び当該製造方法により得ることができる三環性化合物
|
|
RU2693480C2
(ru)
|
2013-03-14 |
2019-07-03 |
Толеро Фармасьютикалз, Инк. |
Ингибиторы jak2 и alk2 и способы их использования
|
|
US8940893B2
(en)
*
|
2013-03-15 |
2015-01-27 |
Boehringer Ingelheim International Gmbh |
Heteroaromatic compounds as BTK inhibitors
|
|
KR102311329B1
(ko)
*
|
2013-03-15 |
2021-10-14 |
얀센 파마슈티카 엔.브이. |
약제를 제조하기 위한 방법 및 중간체
|
|
CN105492011A
(zh)
|
2013-04-08 |
2016-04-13 |
丹尼斯·M·布朗 |
不理想给药化学化合物的治疗增效
|
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
SG11201506764WA
(en)
|
2013-04-25 |
2015-09-29 |
Beigene Ltd |
Fused heterocyclic compounds as protein kinase inhibitors
|
|
GB201309085D0
(en)
|
2013-05-20 |
2013-07-03 |
Redx Pharma Ltd |
Compounds
|
|
CA2938626A1
(en)
|
2013-07-26 |
2015-01-29 |
John Rothman |
Compositions to improve the therapeutic benefit of bisantrene
|
|
TWI649081B
(zh)
|
2013-08-02 |
2019-02-01 |
製藥公司 |
治療固態腫瘤之方法
|
|
ES2709509T3
(es)
|
2013-08-12 |
2019-04-16 |
Pharmacyclics Llc |
Procedimientos para el tratamiento de cáncer amplificado por HER2
|
|
EP3037424B1
(en)
*
|
2013-08-22 |
2017-11-08 |
Taiho Pharmaceutical Co., Ltd. |
Novel quinoline-substituted compound
|
|
NZ718190A
(en)
|
2013-08-23 |
2017-10-27 |
Neupharma Inc |
Substituted quinazolines for inhibiting kinase activity
|
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
|
JP6623353B2
(ja)
|
2013-09-13 |
2019-12-25 |
ベイジーン スウィッツァーランド ゲーエムベーハー |
抗ｐｄ−１抗体並びにその治療及び診断のための使用
|
|
KR20160062103A
(ko)
|
2013-09-30 |
2016-06-01 |
파마싸이클릭스 엘엘씨 |
브루톤 티로신 키나제의 억제제
|
|
WO2015057992A1
(en)
|
2013-10-16 |
2015-04-23 |
Izumi Raquel |
Btk inhibitors for hematopoietic mobilization
|
|
CA2929747C
(en)
|
2013-12-13 |
2018-01-23 |
F. Hoffmann-La Roche Ag |
Inhibitors of bruton's tyrosine kinase
|
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
BR112016016844A2
(pt)
*
|
2014-02-03 |
2017-08-08 |
Cadila Healthcare Ltd |
Compostos heterocíclicos
|
|
KR20160117614A
(ko)
|
2014-02-21 |
2016-10-10 |
프린시피아 바이오파마, 인코퍼레이티드 |
Btk 억제제의 염 및 고체 형태
|
|
EP3119910A4
(en)
|
2014-03-20 |
2018-02-21 |
Pharmacyclics LLC |
Phospholipase c gamma 2 and resistance associated mutations
|
|
US9937171B2
(en)
|
2014-04-11 |
2018-04-10 |
Acerta Pharma B.V. |
Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
|
|
WO2015164213A1
(en)
|
2014-04-23 |
2015-10-29 |
The Research Foundation For The State University Of New York |
A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
|
|
CN105017256A
(zh)
*
|
2014-04-29 |
2015-11-04 |
浙江导明医药科技有限公司 |
多氟化合物作为布鲁顿酪氨酸激酶抑制剂
|
|
WO2015172713A1
(zh)
*
|
2014-05-13 |
2015-11-19 |
广东东阳光药业有限公司 |
一种中间体的制备方法
|
|
CN104086551B
(zh)
*
|
2014-06-06 |
2016-09-21 |
人福医药集团股份公司 |
化合物及其制备方法和用途
|
|
GB201410430D0
(en)
|
2014-06-11 |
2014-07-23 |
Redx Pharma Ltd |
Compounds
|
|
KR102003754B1
(ko)
|
2014-07-03 |
2019-07-25 |
베이진 엘티디 |
Pd-l1 항체와 이를 이용한 치료 및 진단
|
|
CN106999494A
(zh)
|
2014-08-01 |
2017-08-01 |
药品循环有限公司 |
布鲁顿酪氨酸激酶的抑制剂
|
|
JP2017523206A
(ja)
|
2014-08-07 |
2017-08-17 |
ファーマサイクリックス エルエルシー |
ブルトン型チロシンキナーゼ阻害剤の新規製剤
|
|
US10005760B2
(en)
|
2014-08-13 |
2018-06-26 |
Celgene Car Llc |
Forms and compositions of an ERK inhibitor
|
|
US10059715B2
(en)
|
2014-10-01 |
2018-08-28 |
Ratiopharm Gmbh |
Acid addition salt of ibrutinib
|
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
|
EA036269B1
(ru)
|
2014-12-18 |
2020-10-21 |
Принсипиа Биофарма Инк. |
Лечение пузырчатки
|
|
EP3042903B1
(en)
|
2015-01-06 |
2019-08-14 |
Impetis Biosciences Ltd. |
Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
|
|
MA41350A
(fr)
*
|
2015-01-14 |
2017-11-21 |
Janssen Pharmaceutica Nv |
Synthèse d'un inhibiteur de la tyrosine kinase de bruton
|
|
CN105481862B
(zh)
*
|
2015-01-21 |
2018-08-21 |
中国科学院合肥物质科学研究院 |
Flt3激酶的新型抑制剂及其用途
|
|
EP3248979B1
(en)
*
|
2015-01-21 |
2021-04-14 |
Hefei Institutes of Physical Science, Chinese Academy of Sciences |
Novel inhibitor of flt3 kinase and use thereof
|
|
CN105859721B
(zh)
*
|
2015-01-22 |
2018-04-17 |
浙江京新药业股份有限公司 |
一种伊布鲁替尼的制备方法
|
|
CN107207519B
(zh)
*
|
2015-02-12 |
2019-11-08 |
正大天晴药业集团股份有限公司 |
伊布替尼的制备方法
|
|
EP3270694A4
(en)
|
2015-02-17 |
2018-09-05 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
IL315294A
(en)
|
2015-03-03 |
2024-10-01 |
Pharmacyclics Llc |
Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
|
|
WO2016141044A1
(en)
|
2015-03-04 |
2016-09-09 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Erbb4 inhibitors and methods of use thereof
|
|
CN106146508A
(zh)
*
|
2015-03-19 |
2016-11-23 |
浙江导明医药科技有限公司 |
优化的联合用药及其治疗癌症和自身免疫疾病的用途
|
|
US9717745B2
(en)
|
2015-03-19 |
2017-08-01 |
Zhejiang DTRM Biopharma Co. Ltd. |
Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
|
|
CN106146516B
(zh)
*
|
2015-04-20 |
2019-02-15 |
北京睿创康泰医药研究院有限公司 |
依鲁替尼药物杂质的制备方法
|
|
EP4112618A1
(en)
*
|
2015-06-03 |
2023-01-04 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
US9394312B1
(en)
*
|
2015-06-14 |
2016-07-19 |
Mark Quang Nguyen |
Ibrutinib prodrugs, pharmaceutical compositions thereof, and methods of use
|
|
WO2016210165A1
(en)
|
2015-06-24 |
2016-12-29 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
CN114685516A
(zh)
|
2015-09-16 |
2022-07-01 |
洛克索肿瘤学股份有限公司 |
用于治疗癌症的作为btk抑制剂的吡唑并嘧啶衍生物
|
|
UA127863C2
(uk)
|
2015-12-16 |
2024-01-31 |
Локсо Онколоджі, Інк. |
Сполуки, які можна застосовувати як інгібітори кінази
|
|
ES2877089T3
(es)
|
2015-12-24 |
2021-11-16 |
Takeda Pharmaceuticals Co |
Cocristal, método de producción del mismo, y medicamento que contiene dicho cocristal
|
|
RU2728827C2
(ru)
*
|
2016-01-05 |
2020-07-31 |
Цзянсу Хэнжуй Медицин Ко., Лтд. |
Кристаллическая форма ингибитора тирозинкиназы брутона и способ её получения
|
|
WO2017125423A1
(en)
*
|
2016-01-19 |
2017-07-27 |
Janssen Pharmaceutica Nv |
Formulations/compositions comprising a btk inhibitor
|
|
US10793566B2
(en)
|
2016-01-21 |
2020-10-06 |
Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. |
Bruton's tyrosine kinase inhibitors
|
|
KR102699906B1
(ko)
*
|
2016-01-21 |
2024-08-29 |
즈보 바이오폴라 창쉥 파마수티컬 컴퍼니 리미티드 |
브루톤 티로신 키나제 억제제
|
|
CN106995446B
(zh)
*
|
2016-01-22 |
2021-07-02 |
山东新时代药业有限公司 |
布鲁顿酪氨酸激酶抑制剂制备方法
|
|
JP6972002B2
(ja)
|
2016-03-11 |
2021-11-24 |
エンジェル・ファーマシューティカル・カンパニー・リミテッド |
ブルトン型チロシンキナーゼを調節する化合物及び方法
|
|
CN107383013B
(zh)
*
|
2016-05-16 |
2020-03-31 |
苏州信诺维医药科技有限公司 |
作为btk抑制剂的吡唑并嘧啶衍生物及其制备方法和药物组合物
|
|
EP3478273A1
(en)
|
2016-06-29 |
2019-05-08 |
Principia Biopharma Inc. |
Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
|
NZ749997A
(en)
|
2016-07-05 |
2022-11-25 |
Beigene Ltd |
Combination of a pd-l antagonist and a raf inhibitor for treating cancer
|
|
AU2017312561B2
(en)
*
|
2016-08-15 |
2022-06-30 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
KR102604975B1
(ko)
|
2016-08-16 |
2023-11-24 |
베이진 스위찰랜드 게엠베하 |
(s)-7-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐)-4,5,6,7-테트라-하이드로피라졸로 [1,5-a] 피리미딘-3-카르복스아미드의 제조 및 그 용도
|
|
EP3500299B1
(en)
|
2016-08-19 |
2023-12-13 |
BeiGene Switzerland GmbH |
Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer
|
|
JP2019529419A
(ja)
|
2016-09-19 |
2019-10-17 |
エムイーアイ ファーマ，インク． |
併用療法
|
|
JOP20190073A1
(ar)
|
2016-10-31 |
2019-04-07 |
Taiho Pharmaceutical Co Ltd |
مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20
|
|
JOP20190113A1
(ar)
*
|
2016-11-18 |
2019-05-15 |
Biocad Joint Stock Co |
مثبطات بروتون تيروزين كيناز
|
|
EP3548046A2
(en)
|
2016-12-03 |
2019-10-09 |
Juno Therapeutics, Inc. |
Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
|
|
WO2018137681A1
(en)
|
2017-01-25 |
2018-08-02 |
Beigene, Ltd. |
Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
|
|
WO2018145280A1
(zh)
*
|
2017-02-09 |
2018-08-16 |
合肥合源药业有限公司 |
Flt3激酶抑制剂或其盐的晶型及其制备方法
|
|
KR102757960B1
(ko)
|
2017-06-26 |
2025-01-22 |
베이진 엘티디 |
간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
|
|
CN110997677A
(zh)
|
2017-08-12 |
2020-04-10 |
百济神州有限公司 |
具有改进的双重选择性的Btk抑制剂
|
|
JP7065103B2
(ja)
|
2017-09-01 |
2022-05-11 |
大鵬薬品工業株式会社 |
エクソン１８及び／又はエクソン２１変異型ｅｇｆｒ選択的阻害剤
|
|
TW201922256A
(zh)
|
2017-10-27 |
2019-06-16 |
中國大陸商浙江導明醫藥科技有限公司 |
治療淋巴樣惡性疾病之方法
|
|
WO2019108795A1
(en)
|
2017-11-29 |
2019-06-06 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
|
|
CN108191871B
(zh)
*
|
2018-01-02 |
2020-02-18 |
成都倍特药业有限公司 |
新型布鲁顿酪氨酸激酶抑制剂及其制备方法和应用
|
|
EP3773591A4
(en)
|
2018-04-05 |
2021-12-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
AXL KINASE INHIBITORS AND THEIR USE
|
|
CN117959303A
(zh)
|
2018-04-13 |
2024-05-03 |
住友制药肿瘤公司 |
用于治疗骨髓增殖性肿瘤和与癌症相关的纤维化的pim激酶抑制剂
|
|
CA3103995A1
(en)
|
2018-07-26 |
2020-01-30 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
|
CN109134472B
(zh)
*
|
2018-09-20 |
2020-02-11 |
浙江理工大学 |
一种3-(4-苯氧基苯基)-1H-吡唑并[3,4-d]嘧啶-4-胺的合成工艺
|
|
CN110964016B
(zh)
*
|
2018-09-29 |
2021-05-28 |
南京药捷安康生物科技有限公司 |
氨基降茨烷衍生物及其制备方法与应用
|
|
CN109369654A
(zh)
*
|
2018-11-20 |
2019-02-22 |
山东大学 |
1，3-二取代-4-氨基吡唑并嘧啶类化合物及其制备方法和应用
|
|
JP2022515198A
(ja)
|
2018-12-19 |
2022-02-17 |
アレイ バイオファーマ インコーポレイテッド |
ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物
|
|
CN113474337A
(zh)
|
2018-12-19 |
2021-10-01 |
奥瑞生物药品公司 |
作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
|
|
CN111454268B
(zh)
*
|
2019-01-18 |
2023-09-08 |
明慧医药（上海）有限公司 |
作为布鲁顿酪氨酸激酶抑制剂的环状分子
|
|
NZ778055A
(en)
|
2019-02-12 |
2025-11-28 |
Sumitomo Pharma America Inc |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
SG11202110085TA
(en)
|
2019-05-31 |
2021-10-28 |
Sichuan Haisco Pharmaceutical Co Ltd |
Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof
|
|
US20220249491A1
(en)
|
2019-06-10 |
2022-08-11 |
Beigene Switzerland Gmbh |
Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor
|
|
CN110606848A
(zh)
*
|
2019-08-27 |
2019-12-24 |
药雅科技(上海)有限公司 |
一种5-氮杂吲哚衍生物Bruton′s酪氨酸激酶抑制剂及其制备方法与用途
|
|
EP4045051A1
(en)
|
2019-10-14 |
2022-08-24 |
Principia Biopharma Inc. |
Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
|
US12521395B2
(en)
|
2019-11-08 |
2026-01-13 |
Nerviano Medical Sciences S.R.L. |
Gem-disubstituted heterocyclic compounds and their use as IDH inhibitors
|
|
CN115348862A
(zh)
|
2020-01-20 |
2022-11-15 |
建新公司 |
用于复发型多发性硬化症(rms)的治疗性酪氨酸激酶抑制剂
|
|
PH12022551787A1
(en)
|
2020-01-22 |
2024-02-12 |
Principia Biopharma Inc |
Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
|
CN113943294A
(zh)
*
|
2020-07-15 |
2022-01-18 |
成都海博为药业有限公司 |
一种作为btk抑制剂的化合物及其制备方法与用途
|
|
TW202221002A
(zh)
*
|
2020-11-25 |
2022-06-01 |
大陸商四川海思科製藥有限公司 |
一種btk降解劑的製備方法
|
|
MX2023006854A
(es)
|
2020-12-10 |
2023-07-20 |
Genzyme Corp |
Forma cristalina de tolebrutinib, metodo de preparacion y uso de la misma.
|
|
CN113004246B
(zh)
*
|
2021-02-22 |
2022-02-01 |
广西医科大学 |
1，3，5-三嗪-2-胺-4，6取代衍生物或其药学上可接受的盐和用途
|
|
US11786531B1
(en)
|
2022-06-08 |
2023-10-17 |
Beigene Switzerland Gmbh |
Methods of treating B-cell proliferative disorder
|
|
EP4611753A1
(en)
|
2022-10-31 |
2025-09-10 |
Sumitomo Pharma America, Inc. |
Pim1 inhibitor for treating myeloproliferative neoplasms
|